Skip to main content

Market Overview

Company News for March 4, 2010 - Corporate Summary

Share:

• Pfizer (NYSE:PFE) led DJIA stocks on the downside yesterday after Medivation (NASDAQ:MDVN) said its experimental treatment for Alzheimer's, Dimebon, developed with Pfizer, failed to show desired results in late-stage  trials

• Anheuser-Busch InBev (NYSE:BUD) posted adjusted earnings of 55 cents a share, up from 44 cents, which missed Zacks projections by 5 cents, on combined revenues up 5% to $9.3 billion

• UBS (NYSE:UBS) upgraded Coca-Cola (NYSE:KO) to "buy" from "neutral," citing solid mid-single digit global volume growth

• Goldman Sachs (NYSE:GS) upgraded Royal Caribbean (NYSE:RCL) to "neutral" from "sell," and raised the price target to $27 from $23

• Piper Jaffray (NYSE:PJC) reiterated an "overweight" rating on Big Lots (NYSE:BIG), but raised the price target to $41 from $38

• Suntech Power (NYSE:STP) posted better-than-expected earnings of 27 cents a share, sharply up from Zacks estimates of 12 cents, on revenues of $583.6 million, well ahead of Zacks estimates of $471 million

• FBR reiterated its "outperform" rating on Anadarko (NYSE:APC) and raised the price target to $90 from $75

• Bank of America (NYSE:BAC) upgraded Disney (NYSE:DIS) to "buy" from "neutral" and raised its price target to $42 from $33

• Limited Brands (NYSE:LTD) reported February same-store-sales rose 10%, versus consensus projections of 9.7% growth

• Pier 1 Imports (NYSE:PIR) forecast fiscal fourth quarter earnings of at least 29 cents a share versus last year's 33 cent loss, up from projections of 25 cents, as margins post a better-than-expected 55.7%. CEO Alex Smith said, "The increase in margin rate during the quarter is attributable not only to less clearance merchandise but also to our initial markups which remained strong"

• Bernstein upgraded BB&T (NYSE:BBT) to "outperform" and downgraded M&T (NYSE:MTB) and Fifth Third (NASD:FITB) to "market perform" from "outperform"

Zacks Investment Research

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

 

Related Articles (APC + BAC)

View Comments and Join the Discussion!